These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 1322988)

  • 1. Probes for narcotic receptor mediated phenomena. 18. Epimeric 6 alpha- and 6 beta-iodo-3,14-dihydroxy-17-(cyclopropylmethyl)-4,5 alpha-epoxymorphinans as potential ligands for opioid receptor single photon emission computed tomography: synthesis, evaluation, and radiochemistry of [125I]-6 beta-iodo-3,14-dihydroxy-17-(cyclopropylmethyl)-4,5 alpha-epoxymorphinan.
    de Costa BR; Iadarola MJ; Rothman RB; Berman KF; George C; Newman AH; Mahboubi A; Jacobson AE; Rice KC
    J Med Chem; 1992 Jul; 35(15):2826-35. PubMed ID: 1322988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 6 beta-[125iodo]-3, 14-dihydroxy-17-methyl-4, 5 alpha-epoxymorphinan ([125I]IOXY-AGO): a potent and selective radioligand for opioid mu receptors.
    Xu H; Goodman CB; Partilla JS; Ni Q; Kayakiri H; Rice KC; Rothman RB
    Synapse; 1995 Feb; 19(2):105-11. PubMed ID: 7725239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid peptide receptor studies. 3. Interaction of opioid peptides and other drugs with four subtypes of the kappa 2 receptor in guinea pig brain.
    Ni Q; Xu H; Partilla JS; de Costa BR; Rice KC; Kayakiri H; Rothman RB
    Peptides; 1995; 16(6):1083-95. PubMed ID: 8532593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective labeling of kappa 2 opioid receptors in rat brain by [125I]IOXY: interaction of opioid peptides and other drugs with multiple kappa 2a binding sites.
    Ni Q; Xu H; Partilla JS; de Costa BR; Rice KC; Rothman RB
    Peptides; 1993; 14(6):1279-93. PubMed ID: 8134311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
    Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
    J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Some pharmacological properties of a newly synthesized 3-acetoxy-6 beta-acetylthio-10-oxo-N-cyclopropylmethyl-dihydronormorphine (KT-95).
    Hosoki R; Niizawa S; Koike K; Sagara T; Kanematsu K; Takayanagi I
    Arch Int Pharmacodyn Ther; 1996; 331(2):136-52. PubMed ID: 8937625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic analysis of transport and opioid receptor binding of [3H](-)-cyclofoxy in rat brain in vivo: implications for human studies.
    Sawada Y; Kawai R; McManaway M; Otsuki H; Rice KC; Patlak CS; Blasberg RG
    J Cereb Blood Flow Metab; 1991 Mar; 11(2):183-203. PubMed ID: 1847702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
    Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB
    J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2,5-Dimethyl-2'-hydroxy-9 alpha- and 9 beta-(3-methylbutyl)-6,7-benzomorphans and N-substituted compounds in the 9 alpha-(3-methylbutyl) series: chemistry, pharmacology, and biochemistry.
    Jacobson AE; Rice KC; Burke TR; Lupinacci L; Mattson MV; Aceto MD; Harris LS
    J Pharm Sci; 1987 Mar; 76(3):248-52. PubMed ID: 3035172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
    Ghirmai S; Azar MR; Polgar WE; Berzetei-Gurske I; Cashman JR
    J Med Chem; 2008 Mar; 51(6):1913-24. PubMed ID: 18298057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Verifying the role of 3-hydroxy of 17-cyclopropylmethyl-4,5α-epoxy-3,14β-dihydroxy-6β-[(4'-pyridyl) carboxamido]morphinan derivatives via their binding affinity and selectivity profiles on opioid receptors.
    Huang B; Gunta R; Wang H; Li M; Cao D; Mendez RE; Gillespie JC; Chen C; Huang LM; Liu-Chen LY; Selley DE; Zhang Y
    Bioorg Chem; 2021 Apr; 109():104702. PubMed ID: 33631465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probes for narcotic receptor mediated phenomena. 5. Narcotic antagonist irreversible ligands based on endoethenotetrahydrooripavine.
    Jacobson AE; Bajwa BS; Streaty RA; Klee WA; Rice KC
    Life Sci; 1983; 33 Suppl 1():159-62. PubMed ID: 6319854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Syntheses of 4,6'-epoxymorphinan derivatives and their pharmacologies.
    Nemoto T; Fujii H; Narita M; Miyoshi K; Nakamura A; Suzuki T; Nagase H
    Bioorg Med Chem; 2008 Apr; 16(8):4304-12. PubMed ID: 18337104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of 14-alkoxymorphinans. 2. (-)-N-(cyclopropylmethyl)-4,14-dimethoxymorphinan-6-one, a selective mu opioid receptor antagonist.
    Schmidhammer H; Burkard WP; Eggstein-Aeppli L; Smith CF
    J Med Chem; 1989 Feb; 32(2):418-21. PubMed ID: 2536439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probes for narcotic receptor-mediated phenomena. 20. Alteration of opioid receptor subtype selectivity of the 5-(3-hydroxyphenyl)morphans by application of the message-address concept: preparation of delta-opioid receptor ligands.
    Bertha CM; Flippen-Anderson JL; Rothman RB; Porreca F; Davis P; Xu H; Becketts K; Cha XY; Rice KC
    J Med Chem; 1995 Apr; 38(9):1523-37. PubMed ID: 7739011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a structurally novel opioid kappa-agonist derived from 4,5-epoxymorphinan.
    Nagase H; Hayakawa J; Kawamura K; Kawai K; Takezawa Y; Matsuura H; Tajima C; Endo T
    Chem Pharm Bull (Tokyo); 1998 Feb; 46(2):366-9. PubMed ID: 9501472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and pharmacological evaluation of an 8 beta-bis(2-chloroethyl)amino opiate as a nonequilibrium opioid receptor probe.
    Fang SN; Bell KH; Portoghese PS
    J Med Chem; 1984 Aug; 27(8):1090-2. PubMed ID: 6086925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of the structural requirements for the kappa-selective opioid receptor antagonist, 6 beta,6 beta'-[ethylenebis(oxyethyleneimino)]bis[17-(cyclopropylmethyl)- 4,5 alpha-epoxymorphinan-3,14-diol] (TENA).
    Botros S; Lipkowski AW; Takemori AE; Portoghese PS
    J Med Chem; 1986 May; 29(5):874-6. PubMed ID: 3009817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence.
    Neumeyer JL; Bidlack JM; Zong R; Bakthavachalam V; Gao P; Cohen DJ; Negus SS; Mello NK
    J Med Chem; 2000 Jan; 43(1):114-22. PubMed ID: 10633042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and characterization of 7-nitrobenzo-2-oxa-1,3-diazole (NBD)-labeled fluorescent opioids.
    Archer S; Medzihradsky F; Seyed-Mozaffari A; Emmerson PJ
    Biochem Pharmacol; 1992 Jan; 43(2):301-6. PubMed ID: 1371213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.